Shares of NewLink Genetics Corp. (NASDAQ: NLNK), a clinical stage biotech with an oncology focus, are rising in response to a secondary offering that ended up priced much better than anticipated. Instead of hammering the stock as expected, yesterday's pricing announcement has lifted the stock 13.7% higher as of 11:58 a.m. EDT.
Continue Reading Below
Last month, NewLink released data that suggests its lead candidate, indoximod, has a shot at earning approval to treat advanced melanoma patients in combination with Keytruda or Opdivo. The news sent the stock screaming higher and prompted the company to initiate a secondary offering to bolster its cash reserves.
Issuing new shares tends to lower stock prices because they reduce each shareholder's slice of any potential profits. It looks like NewLink is bucking the trend and actually rising today because it priced the 5 million shares it intends to offer the public at $10.25 per share, which is a bit more than expected.
NewLink finished June with about 29.3 million shares outstanding and $107.8 million in cash and cash equivalents on its balance sheet. If the offering is successful, NewLink's share count will rise about 19.6%, padding its balance sheet with roughly another $50 million.
The company burned through $37.6 million this year, and combination studies with indoximod and Keytruda aren't expected to complete enrollment until the end of 2018. While today's offering will extend the company's cash runway, it might not be long enough to achieve liftoff.
10 stocks we like better than NewLink GeneticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and NewLink Genetics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017